Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.777610
Title: Formulation of novel buccal mucosal drug delivery systems for nicotine replacement therapy (NRT)
Author: Okeke, Obinna Chikwado
ISNI:       0000 0004 7963 3870
Awarding Body: University of Greenwich
Current Institution: University of Greenwich
Date of Award: 2017
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
Hydroxypropylmethylcellulose (HPMC) and sodium alginate (SA) were used in the formulation of composite wafers and films for potential nicotine (NIC) replacement therapy via the buccal mucosa route. Composite blank (BK), drug loaded (DL) HPMC-SA films (optimized with 2% w/v plasticizer) and wafers (optimized by freeze drying; annealing) were formulated. Further, nicotine stabilisation using MAS (magnesium aluminium silicate) in optimised composite HPMC-SA films and wafers were undertaken. Formulation characterisation was performed using texture analyser (TA) (mechanical and mucoadhesion properties), scanning electron microscopy (SEM) (surface and internal morphology), X-ray diffractometry (XRD) (physical form), attenuated total reflectance - Fourier transform infrared (ATR-FTIR) spectroscopy (physical interactions), thermo gravimetric analysis (TGA), differential scanning calorimetry (DSC), (thermal profiles) and high-performance liquid chromatography (HPLC) (drug loading efficiency and release). NIC stabilisation was required due to challenges of volatility and oxidative degradation associated with NIC especially for films (< 35% drug loading efficiency). The incorporation of magnesium aluminium silicate (MAS) (optimum concentration; 0.25% w/v) was therefore necessary to stabilise NIC in HPMC-SA composite wafers and films. Optimized wafers and films (HPMC-SA, 1.25:0.75% w/v) were selected based on the physicochemical properties including drug loading efficiency of wafers and films (>90% NIC). The optimized formulations were used to demonstrate the effect of constituents of simulated saliva (SS) in mucoadhesion, hydration and swelling, and release of NIC, which was further compared with commercially available NiQuitin® strips. In comparison with NiQuitin® strips, optimized wafers and films containing MAS demonstrated NIC stability and a slower release from a mucoadhesive system suitable for targeted buccal drug delivery. Finally, wafers demonstrated a higher permeation flux (140.55±47.55mg/cm2/hr) than films (42.31±5.22mg/cm2/hr), and can be considered safe (≥ 70% viable cells).
Supervisor: Boateng, Joshua Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.777610  DOI: Not available
Keywords: RS Pharmacy and materia medica
Share: